A Multicenter, Prospective, Double-Blind, Randomized, Placebo-Controlled, 6-Month Study to Establish the Effect of Fluvastatin 40 mg (b.i.d.) [twice per day] in the Prevention of the Development of Vascular Graft Disease in de Novo Renal Transplant Patients.

Trial Profile

A Multicenter, Prospective, Double-Blind, Randomized, Placebo-Controlled, 6-Month Study to Establish the Effect of Fluvastatin 40 mg (b.i.d.) [twice per day] in the Prevention of the Development of Vascular Graft Disease in de Novo Renal Transplant Patients.

Completed
Phase of Trial: Phase IV

Latest Information Update: 28 Feb 2017

At a glance

  • Drugs Fluvastatin (Primary)
  • Indications Vascular disorders
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 03 Jan 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top